Seribantumab
Based on 1 Customer Validation
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 96.043%
- CAS No.: 1334296-12-6
- 분자량:143.14 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
All EGFR Isoforms
More
Biological Activity
Human IgG2 lambda
Human
ERBB3/HER3
Seribantumab (0.1 nmol/L-10 μmol/L; 96 h) dose-dependently inhibits two cell lines that harbor NRG1 rearrangements (MDA-MB-175-VII, DOC4-NRG1 fusion and LUAD-0061AS3, SLC3A2-NRG1 fusion) with IC50 values of 0.02, 1.4, 45.2 and 203 μmol/L for MDA-MB-175-VII, LUAD-0061AS3, MCF-7 and HBECp53 cells, respectively[1]. Seribantumab (0.1, 1, and 10 μmol/L; 24-48 h) effectively inhibits growth of tumor cell lines that harbor NRG1 fusions or NRG1 amplification[1]. Seribantumab (0-0.5 μmol/L; 96 h) largely suppresses growth of NRG1-b1-stimulated MCF-7 cells[1]. Seribantumab (0-10 μmol/L; 48 h) induces apoptosis of cells harboring NRG1 rearrangements[1]. Seribantumab (0-10 μmol/L; 1 h) inhibits phosphorylation of downstream mediators in cells with NRG1 alterations[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-175-VII and LUAD-0061AS3 cell lines
-
Concentration:0-10 μmol/L
-
Incubation Time:48 hours
-
Result:Dose-dependently increased caspase 3/7 activity and induced apoptosis of NRG1 fusion-positive breast and lung cancer cell lines.
-
Cell Line:LUAD-0061AS3 and HBECp53-CD74-NRG1 cell lines
-
Concentration:0, 0.001, 0.01, 0.1, 1 and 10 μmol/L
-
Incubation Time:1 hour
-
Result:Inhibited the phosphorylation of EGFR, HER2, HER3, HER4, AKT and STAT3 in LUAD-0061AS3 cells. Completely inhibited HER3, AKT, p70S6K and STAT3, and reduced phosphorylation of HER2, EGFR and HER4 to a lesser extent in HBECp53-CD74-NRG1 cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Immunocompromised mice with LUAD-0061AS3 PDX tumors implanted[1]
-
Dosage:0.6, 0.75 and 1 mg
-
Administration:Intraperitoneal injection; 0.6, 0.75 and 1 mg for once
-
Result:Effectively reduced tumor growth of mice and time- and dose-dependently reduced phosphorylation of HER2, HER3, AKT, and ERK1/2. Induced the expression if proapoptotic protein, BIM.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG2 lambda
ELISA, FACS, Functional assay
-
Immobilized HER3 Protein, Human (HEK293, His, HY-P72625) can bind Seribantumab. The EC50 for this effect is 7.53 ng/mL. -
Flow cytometric analysis of 1X106 MCF-7 cells labeling Seribantumab (HY-P99268, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG2 lambda (HY-P991206, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1334296-12-6
-
Appearance Liquid
-
분자량 143.14 kDa
-
Color Colorless to light yellow
-
SMILES
[Seribantumab]
-
Synonyms
SAR 256212; MM 121
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (262 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)